Gujarat Themis Biosyn Limited has informed the Exchange that Record date for the purpose of Dividend is 05-Sep-2025.
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Themis Biosyn's board approved standalone unaudited results for Q1 FY26 (quarter ended June 30, 2025). Total income came in at ₹3,614.72 lakhs, down from ₹3,935.17 lakhs a year ago, while net profit fell sharply to ₹906.16 lakhs from ₹1,323.62 lakhs in Q1 FY25, with EPS dropping to ₹0.83 from ₹1.21. The board fixed September 5, 2025 as the record date to determine shareholders eligible for the dividend for FY25. Separately, the company has called off its proposed merger with Themis Medicare Limited, choosing instead to focus on its core fermentation-based pharmaceutical intermediates and API business. A new multi-purpose API plant at Vapi commenced commercial production on May 1, 2025, aimed at boosting exports to the US and Europe.
The sharp ~31% drop in Q1 profit despite stable revenues may weigh on short-term sentiment, though the new API plant's commissioning and decision to walk away from the merger signal a sharper strategic focus. The fixed record date confirms a dividend will be paid to shareholders on record as of September 5, 2025.